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cense.Abstract Introduction: Renal involvement affects about 50% of SLE patients accounting for sig-
niﬁcant morbidity and mortality in these patients. The adipokine ‘‘visfatin’’ acting as a growth fac-
tor for B-lymphocyte-precursors, exerts several proinﬂammatory functions. It was demonstrated as
a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD) thus could be a factor
linking inﬂammation in SLE and kidney disease.
Aim of the work: To assess serum visfatin level in SLE patients and its correlation to disease
activity and lupus nephritis (LN) in these patients.
Patients and methods: Serum level of visfatin using enzyme-linked immunosorbent assay
(ELISA), chemical and immunological markers of SLE and LN were measured in 40 SLE patients
and 40 age and sex matched healthy controls. Disease activity and renal involvement were assessed
using SLE Disease Activity Index (SLEDAI) and Renal SLEDAI respectively further dividingrtment of Physical Medicine,
ulty of Medicine, Ain Shams
ypt.
com (N. Abaza).
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10 N. Fouda et al.patients into active versus inactive and LN versus non-LN respectively. Renal biopsies were taken
from LN subgroup and were classiﬁed according to the modiﬁed WHO classiﬁcation.
Results: A signiﬁcantly higher serum visfatin level was found on comparing SLE patients (mean
109 ± 180 ng/ml, median18) with controls (mean 9.4 ± 11 ng/ml, median2.5) with statistically
highly signiﬁcant difference (z= 5.2, P< 0.001). Also there was a statistically signiﬁcant difference
as regards serum visfatin level between active SLE patients (mean 173 ± 111 ng/ml, median 14) and
inactive patients (mean 139 ± 88 ng/ml, median 5) (z= 2.1, P< 0.05) as well as between patients
with LN (mean 226 ± 180 ng/ml, median18) and patients with no LN (mean 101 ± 140 ng/ml,
median 8(2-229)) (z= 2.1, P< 0.05). Visfatin had a highly signiﬁcant positive correlation with dis-
ease duration (r= 0.48, P< 0.001), SLEDAI (r= 0.62, P< 0.001) as well as ESR, CRP and,
renal score (r= 0.45, 0.35, and 0.65, respectively) while inverse correlation with estimated GFR
(r= 0.614) and C3 and C4 titre (r= 0.26, r= 0.35, respectively) was recorded. Visfatin
showed high sensitivity in detecting active SLE and LN 83% and 85%, respectively.
Conclusion: Serum visfatin is strongly associated with LN in SLE patients and is a promising
biomarker for prediction of renal involvement in these patients. It reﬂects SLE activity specially
LN activity namely renal score and GFR decline. Further prospective studies are required to con-
ﬁrm visfatin as a destructive mediator of predictive and prognostic value in active lupus nephritis.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic inﬂammatory
multisystem disease mainly affecting women of childbearing
age. It is characterized by a very large spectrum of clinical
manifestations accompanied by prototypic abnormalities of
the immune system. While recent advances in therapeutic
approaches have taken place, SLE still has a profound impact
on the quality of life and life expectancy of affected persons [1].
Kidney involvement is a major concern in SLE, affecting
50% of patients and accounting for signiﬁcant morbidity
and mortality. Its clinical presentations are highly variable,
ranging from mild asymptomatic proteinuria and/or hematu-
ria to rapidly progressive uremia. Early diagnosis and prompt
treatment may dramatically modify the course of renal disease
and improve the long term survival [2].
The term ‘adipokine’ is generally applied to biologically
active substances found in the adipocytes of White Adipose
Tissue (WAT); however, these factors are synthesized at other
sites and participate in functions unrelated to those within
WAT [3]. There has been much effort recently to deﬁne the
role of adipokines in the interaction between adipose tissue,
inﬂammation and immunity [4].
Leptin, adiponectin and resistin are the most extensively
studied adipokines. Leptin may promote inﬂammation by
inducing Th1 phenotype development, where as adiponectin
may combat inﬂammation by reducing the production of
pro-inﬂammatory cytokines. Resistin belongs to a family of
proteins found in foci of inﬂammation, where they contribute
to the inﬂammatory response. All three adipokines have been
detected in synovial ﬂuid from joints affected with the inﬂam-
matory disease rheumatoid arthritis (RA) or the degenerative
disease osteoarthritis (OA) [5].
One of the most recently identiﬁed adipokines is visfatin [6],
originally discovered in liver, skeletal muscle and bone marrow
as a growth factor for B lymphocyte precursors (whence its
alternative name, pre-B-colony enhancing factor, or PBEF).
Interestingly, it has also been implicated to be produced by
immune cells (e.g. neutrophils and macrophages) [7]. Visfatin
synthesis is regulated by several factors, includingglucocorticoids, TNF, IL-6 and growth hormone and it has
been recently demonstrated to exert several pro-inﬂammatory
functions [8].
Visfatin has insulin-mimetic effects and exists in high levels
in foam cell macrophages within unstable atherosclerotic
regions that play a role in plaque destabilization [9]. Plasma
visfatin concentration is related to endothelial dysfunction in
type 2 diabetic patients [10]. Also, patients with inﬂammatory
bowel disease (IBD) were found to have elevated circulating
visfatin levels and increased levels of visfatin mRNA in their
intestinal epithelium [11]. Furthermore, visfatin is also
reported as nicotinamide phosphoribosyltransferase (Nampt),
which is an essential enzyme in the nicotinamide adenine
dinucleotide (NAD) biosynthetic pathway [12].
In addition, circulating visfatin is higher in patients with
RA than in healthy controls. Visfatin expression is detected
in synovial ﬁbroblasts in RA patients and visfatin itself
activates the nuclear factor-kappa B (NF-kB) and related
various proinﬂammatory cytokines in cultured synovial
ﬁbroblasts [13]. More recently, Gomez et al., 2011 studied
serum and synovial ﬂuid visfatin in RA patients and found
them signiﬁcantly higher in all RA patients and patients
with active disease compared to the control group and Nev-
een patients in remission. Serum Visfatin was positively cor-
related with disease activity in RA [14]. Moreover, OA
patients had higher synovial ﬂuid (SF) visfatin concentration
compared to control that increases with OA severity. SF
visfatin positively correlated with degradation biomarker of
collagen II and aggrecan suggesting its involvement in carti-
lage matrix degradation [15].
Recently, visfatin, was shown to be associated with soluble
vascular cell adhesion molecule-1 (sVCAM-1) and act as a
marker of endothelial dysfunction (ED) in chronic kidney
disease (CKD) and could be a factor linking inﬂammation
and kidney disease [16]. Collectively, these results suggest a
new physiological role of visfatin in organ injury and could
be a factor linking inﬂammation and kidney disease.
The aim of this study was to assess the level of serum visf-
atin in SLE patients and to detect any possible correlation to
disease activity and lupus nephritis in these patients.
Table 1 Laboratory data of the SLE patients.
Mean ± SD Range
ESR (mm/h) 70.1 ± 31 30–120
CRP (mg/dl) 11.1 ± 4 6–22
Hb (g/dl) 9.3 ± 2.2 6–13
WBC/lL 3527.6 ± 404.19 2900–4100
Platelets/lL 111426.3 ± 48190.9 87,000–160,000
Creatinine (mg/dl) 1.55 ± 1 0.7–7
Proteinuria (g/24 h) 1.6 ± 1 0.1–7.3
GFR (ml/min/1.73 m2) 55 ± 22 10–90
C3 (mg/dl) 70 ± 25 25–100
C4 (mg/dl) 8.1 ± 3 4–16
Visfatin (ng/ml) 109 ± 180 0.1–995
ESR= erythrocyte sedimentation rate, Hb = hemoglobin,
WBC= white blood cells, GFR= glomerular ﬁltration rate,
CRP= C reactive protein.
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The present study is a cross sectional one that included 40
patients with SLE fulﬁlling the updated American College
of Rheumatology (ACR) criteria [17]. They were selected
the Rheumatology and Nephrology in and out-patient
departments in Ain Shams University Hospitals. Forty age
and sex matched healthy subjects were also included in the
study and served as control group. All the patients were
on steroids and cytotoxic drugs. Oral consent was obtained
from all patients and controls after a full explanation of
the study.
2.1. Exclusion criteria
Patients with diabetes mellitus, malignancies, overlap syn-
drome, metabolic syndrome, liver disease, IBD or on hemodi-
alysis were excluded from the study.
2.2. Clinical assessment
– Full history taking laying stress on disease duration, drug
history.
– Clinical assessment of the patients which included the
following:
 BMI (kg/m2) was determined by weight (kg) and height (m)
(Quelet index).
 Assessment of the disease activity using SLE Disease activ-
ity index (SLEDAI) which is a validated model of experi-
enced clinicians’ global assessments of disease activity in
SLE patients with active disease 8 or more points [18].
 Lupus nephritis was assessed clinically with the renal SLE
disease activity index (renal SLEDAI) [18] which consists
of the 4 kidney related parameters: hematuria, pyuria,
proteinuria and urinary casts. Each item in renal SLEDAI
was assigned 4 points. Thus the scores for the renal SLE-
DAI can range from 0 to a maximum of 16. Patients were
diagnosed to have lupus nephritis if (renal SLEDAI
score>8) i.e. at least 2 abnormal results for renal
parameters.
2.3. Laboratory assessment
– Complete blood picture.
– Erythrocyte sedimentation rate (ESR) using Westergren
method.
– CRP using latex agglutination method.
– Autoantibodies measurement: Anti-nuclear antibody and
Anti-dsDNA and complements.
– Kidney function tests: creatinine, urea, albumin and albu-
min globulin ratio and glomerular ﬁltration rate
– Urine analysis with 24 hours sample.
– Serum complement C3 and C4 (assessed by nephelometry).
– Measurement of serum visfatin was done by enzyme
linked immunosorbent assay (ELISA) for quantitative
determination of visfatin in human serum, detection range
(1.56-100 ng/ml). The intra-assay coefﬁcient of variations
was 5.6. Plasma was stored frozen at –80 C until
measurement.2.4. Renal biopsy
Renal biopsies were taken from the patients with LN. Serum
samples had to be taken at the time of the renal biopsy ± 7 -
days and were stored at 80 C until further use. All biopsies
were classiﬁed according to the modiﬁed WHO classiﬁcation
into six classes [19,20] normal, mesangial, focal segmental, dif-
fuse proliferative, membranous or advanced sclerosis. The
classiﬁcation was done on the basis of the most prominent
lesion.
The statistical analysis was performed by IBM SPSS
statistics (V. 19.0, IBM Corp., USA, 2010) used for data
analysis. Data were expressed as Mean ± SD for quantitative
measures.
The following tests were done:
1. Comparison of two independent mean groups for paramet-
ric data using Student t test.
2. Comparison between two independent groups for non-
parametric data using Wilcoxon Rank Sum test.
3. Ranked Spearman correlation test to study the possible
association between each two variables among each
group.
3. Results
3.1. Clinical and laboratory data of SLE patients
This study included 40 female patients with SLE; their ages
ranged from 19 to 30 years (mean 24.36 ± 3.4). The disease
duration ranged from 0.5 to 6 years (mean 3.26 ± 1.74). The
body mass index (BMI) ranged from 19 to 31 kg/m2 (mean
23.7 ± 3). SLE patients were on steroid dosage ranging from
5-15 mg daily (mean 7.895 ± 3.03).
Evaluation of disease activity by SLEDAI ranged from 2 to
67 (mean 23.15 ± 18.14) and the renal score ranged from 0 to 16
(mean 6.94 ± 4.18). The visfatin level ranged from 0.1 to
995 ng/ml (mean 109 ± 180). The other laboratory data of the
patients are shown in (Table 1).
All patients had within normal liver function tests values.
Table 2 Comparison between patients and control as regards serum visfatin.
Variables SLE pts Controls Z P
N= 40 N= 40
Mean visfatin ± SD (ng/ml) 109 ± 180 9.4 ± 11 5.2 <0.001
Median visfatin (ng/ml) (IQR) 18 (5.5–226) 2.5 (0.6–25) HS
Table 3 Comparison between active and inactive cases as regard different variables.
Variables Active N= 19 Inactive N= 21 t P
Age (years) 23.9 ± 3 24.8 ± 4 0.9 >0.05
NS
DD (years) 3.2 ± 1.3 3.4 ± 1.1 0.3 >0.05
NS
BMI (kg/m2) 23.5 ± 3 23.8 ± 4 0.8 >0.05
NS
Renal score 7.4 ± 3 6.3 ± 3 1.3 >0.05
NS
ESR (mm/hr) 70 ± 24 49 ± 30 3.5 <0.001
HS
CRP (mg/dl) 11.4 ± 4 6.8 ± 3 2.3 <0.05
S
Hb (gm/dL) 8.9 ± 4 9.7 ± 4 0.8 >0.05
NS
Creatinine (mg/dl) 1.7 ± 3 1.4 ± 2 0.9a >0.05
NS
Proteinuria (g/24 hrs) 1.9 ± 3 1.4 ± 1.8 0.4a >0.05
NS
GFR (ml/min/1.73m2) 53 ± 20 57 ± 22 0.7 >0.05
NS
C3 (mg/dl) 60.9 ± 28 74 ± 22 2.9 <0.05
S
C4 (mg/dl) 7.4 ± 3 8.7 ± 4 1.6 >0.05
NS
Visfatin (ng/ml) 173 ± 111 139 ± 88
14 (6–220)a 5 (6–110)a 2.1 <0.05
S
DD= disease duration, BMI = body mass index, ESR= erythrocyte sedimentation rate, CRP = C reactive protein, Hb = hemoglobin,
GFR= glomerular ﬁltration rate.
a Median interquartile range (IQR).
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Comparison between patients and controls as regards mean
value of BMI (mean 23.7 ± 3) and (mean 23.53 ± 2.47),
respectively revealed statistically non signiﬁcant difference
(P>0.05). There was statistically highly signiﬁcant difference
(z 5.2, P< 0.001) as regards serum visfatin between patients
(mean 109 ± 180, median interquartile range [IQR] 18), and
controls (mean 9.4 ± 11, median [IQR] 2.5 (Table 2).
3.3. Comparison between active and inactive SLE patients
By using SLEDAI for assessment of disease activity, there
were 19 active patients (47.5%) with their SLEDAI > 8. While
the other 21 patients (52.5%) were inactive (SLEDAI < 8).
The active group had a higher ESR and CRP and a lower
C3 compared to the inactive group. While there was statisti-
cally non signiﬁcant difference between both groups as regardsage, disease duration, renal score and other laboratory data
(Table 3).
The Visfatin level was signiﬁcantly higher among the active
(mean 173 ± 111, median 14) compared to the inactive group
(mean 139 ± 88, median 5) (z 2.1, P< 0.05) using Mann
Whitney Willcoxon U test (Table 3).
3.4. Comparison between SLE patients with and without lupus
nephritis
Assessment of lupus nephritis by renal SLEDAI, revealed that
22 patients (55%) had lupus nephritis (renal SLEDAI
score>8) while 18 patients (45%) had no lupus nephritis (renal
SLEDAI score < 8). There was a statistically signiﬁcant dif-
ference between both groups as regards SLEDAI and C4 level
while there was statistically non signiﬁcant difference between
both groups as regards age, disease duration and other labora-
tory data (Table 4).
Table 4 Comparison between cases with and without lupus nephritis as regard different variables.
Variables Lupus nephritis N= 22 No nephritis N= 18 t P
Age (years) 24.9 ± 6 23 ± 5 0.4 >0.05
DD (years) NS
3.1 ± 1.6 3.5 ± 1.4 0.6 >0.05
BMI (kg/m2) NS
23.6 ± 4 23.7 ± 5 0.3 >0.05
SLEDAI NS
25.2 ± 10 21.9 ± 6 2.1 <0.05
ESR (mm/h) S
71 ± 3 69 ± 3 1.1 >0.05
CRP (mg/dl) NS
11.2 ± 4 10.9 ± 4 0.7 >0.05
Hb (gm/dL) NS
9.4 ± 3 9.3 ± 2 0.6 >0.05
Creatinine (mg/dl) NS
1.2 ± 2 1.4 ± 2 0.3 >0.05
Proteinuria (g/24 h) NS
1.9 ± 2 1.3 ± 1.8 0.8 >0.05
GFR (ml/min/1.73 m2) NS
53 ± 20 59 ± 21 0.7 >0.05
C3 (mg/dl) NS
70 ± 35 69 ± 30 0.3 >0.05
C4 (mg/dl) NS
6.5 ± 1.5 8.4 ± 2 2.4 <0.05
S
DD= disease duration, BMI = body mass index, SLEDAI = systemic lupus erythematosus disease activity index, ESR= erythrocyte sedi-
mentation rate, CRP = C reactive protein, Hb = hemoglobin, GFR= glomerular ﬁltration rate.
Table 5 Comparison between cases with and without lupus nephritis as regards visfatin level.
Variables Pt with LN (N= 22) Pt with no LN (N= 19) Z P
Mean visfatin ± SD (ng/ml) 226 ± 180 140 ± 101 2.1 <0.05 S
Median visfatin (ng/ml) (IQR) 18 (6.2–112) 8 (2–229)
Figure 1 Correlation between serum visfatin and renal biopsy
class (according to WHO classiﬁcation grading).
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patients with no nephritis as regards serum visfatin showed
that visfatin level was signiﬁcantly higher among the LN
compared to the non-lupus nephritis group (mean 226 ±
180, median 18(6.2-112) versus (mean 140 ± 101, median
8(2-229)) (P< 0.05), (Table 5).
Low C3 and normal C4 concentrations were found in only
1 patient (5%). Normal C3 and low C4 concentrations (74%)
were commonest in lupus nephritis group. Two patients (11%)
with lupus nephritis showed low C3 in the presence of low C4
concentration. There were 10% with normal C3 and C4.
3.5. Correlation between visfatin levels and studied variables in
SLE
Renal biopsies were taken from the patients with LN (n = 22).
The majority of patients had II, III or IV lupus nephritis (LN).
All patients had a positive staining for glomerular C3. Three of
the 22 patients had class V (membranous) lupus nephritis
corresponding to a class Va nephritis according to the modi-
ﬁed 1982 WHO classiﬁcation according to Weening et al. in
2004 [19,20]. The other LN patients (n = 19) were classes
II–IV and considered as active (proliferative) lupus nephritis.Assessment of visfatin was done at the time of renal biopsy
and it correlated signiﬁcantly with the grades of renal biopsy
(0.32, P< 0.05) (Fig. 1).
Figure 2 Correlation between Visfatin and SLEDAI score.
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clinical data of SLE patients showed a statistically highly signif-
icant correlation (P< 0.001) between the visfatin and duration
of disease (r 0.48), SLEDAI (r 0.62) and renal score (r 0.65) (ﬁg.
2 and 3). As regards laboratory data, a positive highly signiﬁ-
cant correlation between the visfatin level and ESR and CRP
was found (r 0.45 and 0.35, respectively). Also a signiﬁcant
inverse correlation existed between visfatin and estimated
GFR (r= 0.614, P< 0.001), C3 as well as C4 titre
(r= 0.614, 0.26, 0.35, respectively). On the other hand
non-signiﬁcant correlations between visfatin and other demo-
graphic and laboratory parameters were recorded (Table 6).
3.6. Validity of visfatin in prediction of SLE activity and lupus
nephritis
For the detection of active SLE, the visfatin assay showed a
sensitivity of (83%) and negative predictive value (85%).
Speciﬁcity and positive predictive value were 60% and 59%,
respectively. The corresponding receiver operating characteris-
tic (ROC) curve is demonstrated in Fig. 4a (area under the
curve = 0.74, 74%, accuracy 62%) (Table 7, Fig. 4a).
For the detection of active lupus nephritis, the visfatin
assay showed a sensitivity of (85%) and negative predictive
value (89%). Speciﬁcity and positive predictive value were
60% and 67%, respectively. The corresponding receiver
operating characteristic (ROC) curve is demonstrated in
Fig. 4b (area under the curve = 0.77, 77%, accuracy 65%)
(Table 7, Fig. 4b).
4. Discussion
SLE is a prototype of an autoimmune syndrome that is char-
acterized by various organ manifestations. Lupus nephritis isTable 6 Correlation between visfatin and different variables
among cases.
Variables Visfatin
r p
Age (years) 0.09 >0.05 (NS)
DD (years) 0.48 <0.001 (HS)
BMI (kg/m2) 0.19 >0.05 (NS)
SLEDAI 0.62 <0.001 (HS)
Renal score 0.65 <0.001 (HS)
ESR (mm/h) 0.45 <0.001 (HS)
CRP (mg/dl) 0.35 <0.001 (HS)
Proteinuria (g/24 h) 0.08 >0.05 (NS)
GFR (ml/min/1.73 m2) 0.614 <0.001 (HS)
Hb (gm/dl) 0.03 >0.05 (NS)
WBC/lL 0.025 >0.05 (NS)
Platelets/lL 0.146 >0.05 (NS)
Creatinine (mg/dl) 0.19 >0.05 (NS)
C3 (mg/dl) 0.26 <0.05 (S)
C4 (mg/dl) 0.35 <0.05 (S)
Renal biopsy class 0.32 <0.05 (S)
Steroid dosage (mg) 0.227 >0.05 (NS)
DD= disease duration, BMI = body mass index, SLE-
DAI = systemic lupus erythematosus disease activity index,
ESR= erythrocyte sedimentation rate, CRP = C reactive protein,
GFR= glomerular ﬁltration rate, Hb = hemoglobin,
WBC= white blood cell.
Figure 3 Correlation between Visfatin and renal score.one of the most serious manifestations of SLE. This organ
manifestation has traditionally been characterized by the
World Health Organization classiﬁcation criteria, which
focuses on histological parameters [19,20]. Visfatin, also
known as pre-B cell colony-enhancing factor (PBEF), is an
adipocytokine that recently generated much interest [11];
however, its role in chronic kidney disease (CKD) remains to
be clariﬁed. This study aimed to assess visfatin in SLE patients
and its correlation with disease activity and lupus nephritis in
these patients.
In this study SLE patients exhibited higher visfatin level
compared with the controls. This is in agreement with Chung
et al. study in 2009 [21] who measured the concentrations of
different adipocytokines as resistin, leptin, adiponectin and
visfatin in 109 patients with SLE and 78 control subjects. They
recorded that serum visfatin was higher in patients with SLE
than in controls. Also, De Sanctis et al., [22] in 2009 reported
the same ﬁndings in their studied SLE patients. They all
concluded that visfatin is involved in the inﬂammation and
metabolic imbalance of patients with SLE. On the other hand,
Ozgen et al. [23] studied serum visfatin level and its association
with common carotid intima-media thickness, which is a
predictor of atherosclerosis, in patients with RA, SLE,
systemic sclerosis (SSc), and Behc¸et’s disease (BD). They stated
Figure 4 (a) Validity of Visfatin in prediction of SLE activity. (b) Validity of Visfatin in prediction of Lupus nephritis (using ROC curve
measuring test accuracy). ROC curve = receiver operating characteristic curve.
Table 7 Validity of visfatin in prediction of SLE activity and
lupus nephritis.
Variables Active SLE Lupus nephritis
Best cut value = 7 7 4
Area under the curve 0.74 0.77
Sensitivity 83% 85%
Speciﬁcity 60% 60%
PPV 59% 67%
NPV 85% 89%
Accuracy 62% 65%
PPV= positive predictive value, NPV= negative predictive value.
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SLE and SSc groups.
Other investigators [4,5,24] have reported the elevated
visfatin level in rheumatic diseases as rheumatoid arthritis
and osteoarthritis. In 2011, Gomez et al. [14] and Duan
et al. [15] published important studies highlighting the impor-
tance of Visfatin in RA and OA, respectively relating it to
disease activity and severity. Other adipokine, adiponectin,
was higher in patients with various autoimmune diseases
including SLE [25]. The physiological role or relevance of
adipokines, namely visfatin, in these inﬂammatory diseases
might involve modulation of the inﬂammatory or immune
response as visfatin induces chemotaxis and increases the
production of IL-1, TNF, IL-6 and costimulatory molecules
by CD14+ monocytes. This increases their ability to induce
alloproliferative responses [26]. Another explanation is that
elevated visfatin level might be also up-regulated during
inﬂammation and in response to pro-inﬂammatory cytokines
or the increased levels could simply be an epiphenomenon [26].
Hence, studies have indicated that visfatin activates human
leukocytes and stimulates the production of pro-inﬂammatory
cytokines [8] More recently, Evans et al. [27] showed that
Visfatin stimulated matrix metalloproteinases production,
synovial inﬂammation and chemokine-directed leukocyteinﬁltration. In this study the positive correlation between
visfatin and CRP supports the role of visfatin as an inﬂamma-
tory mediator. This is also in accordance with Oki study in
2007 [28] who reported also this positive correlation. They
concluded that the elevated concentrations of visfatin could
reﬂect systemic inﬂammation. This is also in accordance with
Bessa et al. [29] who found serum visfatin, VCAM-1, CRP
were signiﬁcantly elevated in CKD patients as compared to
controls and that Visfatin correlated positively with
VCAM-1 and CRP.
The ﬁnding that PBEF/visfatin is preferentially expressed
and secreted by visceral adipose has mainly, though not
universally, been upheld in many studies denoting visfatin
levels are more pronounced in obese humans. One hypothesis
is that the hypoxia that occurs as fat cells increase in size can
induce visfatin expression [30]. Another hypothesis notes that
macrophages are more prevalent in obese adipose tissue, espe-
cially surrounding apoptotic adipocytes. These macrophages
join adipocytes in producing visfatin [31]. Regardless of how
a visfatin differential is created, once it exists it has the ability
to promote adipogenesis [6].
However, this study did not ﬁnd a statistical correlation
between visfatin levels with the BMI may be because of the
small number of SLE patients with their BMI within normal
range; (23.7 ± 3 kg/m2).
Data from Yilmaz and his colleagues study in 2008 [16]
support our observation of the inverse correlation between
circulating visfatin level and GFR. They studied 406 patients
with different stages of CKD while 80 healthy volunteers
served as matched controls. Visfatin levels were strongly corre-
lated with the decrease in GFR. They explained these results:
that recently, visfatin, was shown to be associated with
sVCAM-1 and acts as a marker of ED in CKD and could be
a factor linking inﬂammation and kidney disease [16,32,33].
This is also in accordance with the study by Mu et al. [34]
who described that CKD patients with higher visfatin levels
were associated with lower GFR and impaired endothelial
function.
16 N. Fouda et al.We found a highly signiﬁcant positive correlation between
the mean values of visfatin and SLEDAI as well as a signif-
icantly higher visfatin among the active SLE group compared
to the inactive group. This is in accordance with the study of
Stofkova who had mentioned that visfatin is up-regulated
during inﬂammation and in response to pro-inﬂammatory
cytokines. He had also added that visfatin itself can contrib-
ute to the inﬂammatory processes by triggering cytokine
production and NF-kappa B activation [26]. The speciﬁc rela-
tionship between visfatin and inﬂammation in SLE as well as
disease activity has not been enough elaborated in further
studies.
In another study by Yilmaz et al., also in 2008 [35] research-
ers analyzed circulating visfatin levels in diabetic nephropathy
patients. They found that with increasing visfatin, patients
proved to have higher degree of proteinuria and suggested it
is an important predictor of endothelial dysfunction in early
diabetic nephropathy. In this study, a positive but non-signif-
icant correlation existed between visfatin and proteinuria.
However to our knowledge, there are only few investigators
who studied this correlation so more studies with larger num-
ber of patients are needed to clarify this correlation.
In this study the LN group had higher visfatin level com-
pared to patients with no LN. Also a highly signiﬁcant positive
correlation between visfatin and renal score was recorded.
Visfatin showed similar speciﬁcity for detection of active SLE
and lupus nephritis, but had more sensitivity, negative and
positive predictive values and more accuracy for detection of
LN than SLE activity. This was in accordance with a study
by Kang et al. [36] who stated that visfatin is produced by renal
cells and has an important paracrine role in the pathogenesis of
nephropathy and was signiﬁcantly higher in presence of
nephritis.
It is now clear that adipokines have multiple important
roles in the body, and the increasing research effort in this area
is gradually revealing the intricate adipokine-mediated inter-
play between adipose tissue, metabolic disorders and inﬂam-
matory autoimmune disorders. New insight into the role of
adipokines makes them attractive targets for novel therapeutic
strategies in chronic inﬂammatory diseases.
In conclusion, serum visfatin is strongly associated with LN
in SLE patients and is a promising biomarker for prediction of
renal involvement in these patients. It reﬂects SLE activity and
LN namely renal score rise and GFR, C3 and C4 decline. Fur-
ther prospective studies are required to conﬁrm visfatin as a
destructive mediator and prognostic factor in active lupus
nephritis.Conﬂict of interest statement
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